MX394380B - Compuestos dinucleótidos cíclicos para eltratamiento de cáncer - Google Patents
Compuestos dinucleótidos cíclicos para eltratamiento de cáncerInfo
- Publication number
- MX394380B MX394380B MX2019009796A MX2019009796A MX394380B MX 394380 B MX394380 B MX 394380B MX 2019009796 A MX2019009796 A MX 2019009796A MX 2019009796 A MX2019009796 A MX 2019009796A MX 394380 B MX394380 B MX 394380B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer treatment
- cyclic dinucleotide
- dinucleotide compounds
- compounds
- cyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6587—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having two phosphorus atoms as ring hetero atoms in the same ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente se proveen compuestos útiles para el tratamiento de cáncer.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460562P | 2017-02-17 | 2017-02-17 | |
| US201762479169P | 2017-03-30 | 2017-03-30 | |
| US201762551645P | 2017-08-29 | 2017-08-29 | |
| US201762551668P | 2017-08-29 | 2017-08-29 | |
| US201762551647P | 2017-08-29 | 2017-08-29 | |
| PCT/US2018/018556 WO2018152450A1 (en) | 2017-02-17 | 2018-02-17 | Cyclic di-nucleotides compounds for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019009796A MX2019009796A (es) | 2019-10-22 |
| MX394380B true MX394380B (es) | 2025-03-24 |
Family
ID=61521844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009796A MX394380B (es) | 2017-02-17 | 2018-02-17 | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US20200055883A1 (es) |
| EP (3) | EP3582853B1 (es) |
| JP (2) | JP6672532B2 (es) |
| KR (1) | KR102645790B1 (es) |
| CN (3) | CN117866030A (es) |
| AU (1) | AU2018221170B2 (es) |
| CA (1) | CA3053932A1 (es) |
| CL (1) | CL2019002304A1 (es) |
| CO (1) | CO2019008783A2 (es) |
| CY (1) | CY1126855T1 (es) |
| DK (1) | DK3582853T3 (es) |
| ES (1) | ES2906299T3 (es) |
| HR (1) | HRP20220110T1 (es) |
| HU (1) | HUE057665T2 (es) |
| IL (1) | IL268721B (es) |
| JO (1) | JOP20190194B1 (es) |
| LT (1) | LT3582853T (es) |
| MA (1) | MA47501A (es) |
| MD (1) | MD3582853T2 (es) |
| MX (1) | MX394380B (es) |
| NZ (1) | NZ757357A (es) |
| PE (1) | PE20191686A1 (es) |
| PH (1) | PH12019501914B1 (es) |
| PL (1) | PL3582853T3 (es) |
| PT (1) | PT3582853T (es) |
| RS (1) | RS62842B1 (es) |
| SG (1) | SG11201907496RA (es) |
| SI (1) | SI3582853T1 (es) |
| SM (1) | SMT202200054T1 (es) |
| TW (1) | TWI766948B (es) |
| UA (1) | UA125310C2 (es) |
| WO (2) | WO2018152450A1 (es) |
| ZA (1) | ZA201906111B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| ES2971271T3 (es) | 2017-01-20 | 2024-06-04 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer |
| KR20250084983A (ko) | 2017-03-27 | 2025-06-11 | 하이드로-퀘벡 | 전해질 조성물에서 또는 전극 첨가제로서 사용하기 위한 염 |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| SG11202004113VA (en) | 2017-11-10 | 2020-06-29 | Takeda Pharmaceuticals Co | Sting modulator compounds, and methods of making and using |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| US11478479B2 (en) | 2018-02-16 | 2022-10-25 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| WO2019232392A1 (en) * | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Methods for the treatment of bladder cancer |
| EP3837268B1 (en) * | 2018-08-16 | 2025-01-15 | Eisai R&D Management Co., Ltd. | Salts of compounds and crystals thereof |
| CN113164618A (zh) | 2018-09-12 | 2021-07-23 | 希沃尔拜克治疗公司 | 用免疫刺激性缀合物治疗疾病的方法和组合物 |
| CN111655712B (zh) * | 2018-12-29 | 2021-02-05 | 上海济煜医药科技有限公司 | 作为肿瘤免疫类的化合物及其应用 |
| WO2020227421A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| US11453681B2 (en) * | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| US20220304982A1 (en) * | 2019-07-01 | 2022-09-29 | Eisai R&D Management Co., Ltd. | System for enhancing therapeutic compliance of the anti-cancer compound e7766 |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| JP2022177332A (ja) * | 2019-10-24 | 2022-12-01 | 日東電工株式会社 | オリゴヌクレオチドを製造する方法 |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| WO2021252904A1 (en) | 2020-06-11 | 2021-12-16 | Massachusetts Institute Of Technology | Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy |
| IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Anti-asgr1 antibody conjugates and uses thereof |
| CN111909223A (zh) * | 2020-07-17 | 2020-11-10 | 清华大学 | 环二核苷酸共价修饰物及其制备方法和应用 |
| WO2022079175A1 (en) | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
| US20220168330A1 (en) | 2020-11-09 | 2022-06-02 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| CN115974974B (zh) * | 2022-09-16 | 2025-10-28 | 上海大学 | 一种具有抗炎活性的多肽类化合物及其制备方法与应用 |
| EP4673474A2 (en) | 2023-02-28 | 2026-01-07 | Eisai R&D Management Co., Ltd. | Anti-psma antibodies, conjugates, and methods of use |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| EP1729781B1 (en) | 2004-03-15 | 2012-10-24 | Karaolis, David K. R. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
| CN102199183B (zh) | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
| SG10201610251PA (en) * | 2012-06-08 | 2017-01-27 | Aduro Biotech | Compositions and methods for cancer immunotherapy |
| PT2931738T (pt) * | 2012-12-13 | 2019-04-10 | Aduro Biotech Inc | Composições compreendendo nucleótidos cíclicos de purina com estereoquímica definida e métodos para a sua preparação e utilização |
| EP4398254A3 (en) * | 2013-04-29 | 2024-10-23 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| US20140329889A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| PT2996473T (pt) | 2013-05-18 | 2019-11-18 | Univ California | Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão'' |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| CA2931146C (en) | 2013-11-22 | 2022-06-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| CR20160564A (es) * | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| US11058758B2 (en) | 2014-11-20 | 2021-07-13 | National Institutes Of Biomedical Innovation, Health And Nutrition | TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same |
| EP3546473B1 (en) | 2014-12-16 | 2025-12-10 | Kayla Therapeutics | Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| WO2016096577A1 (en) * | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| CN107106589A (zh) | 2014-12-17 | 2017-08-29 | 立博美华基因科技有限责任公司 | 用cGAMP或cGAsMP治疗癌症的方法 |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| TW201717968A (zh) | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物 |
| EP3325473A4 (en) | 2015-07-22 | 2019-06-26 | The Royal Institution for the Advancement of Learning / McGill University | Compounds and uses thereof in the treatment of cancer and other medical disorders |
| SG10202010609QA (en) | 2015-08-13 | 2020-11-27 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
| US9809597B2 (en) | 2015-08-20 | 2017-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy |
| CN108289912A (zh) | 2015-09-01 | 2018-07-17 | 先天肿瘤免疫公司 | 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途 |
| EP3368072A4 (en) | 2015-10-28 | 2019-07-03 | Aduro BioTech, Inc. | COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE |
| RU2020113165A (ru) | 2015-12-03 | 2020-06-09 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
| JP6801956B2 (ja) | 2015-12-04 | 2020-12-16 | 株式会社エクセディ | モータサイクル用クラッチ装置 |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| CN109451740B (zh) | 2016-01-11 | 2022-09-02 | 先天肿瘤免疫公司 | 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸 |
| EP3692996A1 (en) | 2016-03-18 | 2020-08-12 | Immune Sensor, LLC | Cyclic di-nucleotide compounds and methods of use |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| EP3574018A4 (en) | 2017-01-27 | 2020-10-07 | Silverback Therapeutics, Inc. | CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE |
| WO2018198084A1 (en) | 2017-04-27 | 2018-11-01 | Lupin Limited | Cyclic di-nucleotide compounds with tricyclic nucleobases |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
-
2018
- 2018-02-16 US US16/486,954 patent/US20200055883A1/en not_active Abandoned
- 2018-02-17 MD MDE20200009T patent/MD3582853T2/ro unknown
- 2018-02-17 NZ NZ757357A patent/NZ757357A/en unknown
- 2018-02-17 UA UAA201909860A patent/UA125310C2/uk unknown
- 2018-02-17 EP EP18708032.0A patent/EP3582853B1/en active Active
- 2018-02-17 JO JOP/2019/0194A patent/JOP20190194B1/ar active
- 2018-02-17 JP JP2019544817A patent/JP6672532B2/ja active Active
- 2018-02-17 RS RS20220079A patent/RS62842B1/sr unknown
- 2018-02-17 WO PCT/US2018/018556 patent/WO2018152450A1/en not_active Ceased
- 2018-02-17 LT LTEPPCT/US2018/018556T patent/LT3582853T/lt unknown
- 2018-02-17 CN CN202410024195.7A patent/CN117866030A/zh active Pending
- 2018-02-17 CN CN201880025317.7A patent/CN110536719A/zh active Pending
- 2018-02-17 MA MA047501A patent/MA47501A/fr unknown
- 2018-02-17 MX MX2019009796A patent/MX394380B/es unknown
- 2018-02-17 HR HRP20220110TT patent/HRP20220110T1/hr unknown
- 2018-02-17 WO PCT/US2018/018561 patent/WO2018152453A1/en not_active Ceased
- 2018-02-17 AU AU2018221170A patent/AU2018221170B2/en active Active
- 2018-02-17 SG SG11201907496RA patent/SG11201907496RA/en unknown
- 2018-02-17 DK DK18708032.0T patent/DK3582853T3/da active
- 2018-02-17 PE PE2019001715A patent/PE20191686A1/es unknown
- 2018-02-17 PL PL18708032T patent/PL3582853T3/pl unknown
- 2018-02-17 US US15/898,533 patent/US10246480B2/en active Active
- 2018-02-17 SM SM20220054T patent/SMT202200054T1/it unknown
- 2018-02-17 HU HUE18708032A patent/HUE057665T2/hu unknown
- 2018-02-17 EP EP21208462.8A patent/EP4008403A1/en not_active Withdrawn
- 2018-02-17 PT PT187080320T patent/PT3582853T/pt unknown
- 2018-02-17 SI SI201830553T patent/SI3582853T1/sl unknown
- 2018-02-17 EP EP18709835.5A patent/EP3582854A1/en not_active Withdrawn
- 2018-02-17 KR KR1020197027073A patent/KR102645790B1/ko active Active
- 2018-02-17 PH PH1/2019/501914A patent/PH12019501914B1/en unknown
- 2018-02-17 ES ES18708032T patent/ES2906299T3/es active Active
- 2018-02-17 CN CN201880021349.XA patent/CN110461416B/zh active Active
- 2018-02-17 CA CA3053932A patent/CA3053932A1/en active Pending
- 2018-02-17 JP JP2019544725A patent/JP2020510638A/ja active Pending
- 2018-02-21 TW TW107105846A patent/TWI766948B/zh active
-
2019
- 2019-02-15 US US16/277,522 patent/US10618930B2/en active Active
- 2019-08-13 CO CONC2019/0008783A patent/CO2019008783A2/es unknown
- 2019-08-14 CL CL2019002304A patent/CL2019002304A1/es unknown
- 2019-08-15 IL IL268721A patent/IL268721B/en unknown
- 2019-09-16 ZA ZA2019/06111A patent/ZA201906111B/en unknown
-
2020
- 2020-02-04 US US16/781,352 patent/US11339188B2/en active Active
-
2022
- 2022-01-26 CY CY20221100065T patent/CY1126855T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| CY1124595T1 (el) | Ρυθμιση δραστικοτητας συμπληρωματος | |
| ECSP17073743A (es) | Moduladores de k-ras | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| CL2017001171A1 (es) | Peptidos macrocíclicos útiles como inmunomoduladores | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| MX2022007801A (es) | Formas polimorficas de rad1901-2hcl. | |
| HUE050155T2 (hu) | 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére | |
| EA201991818A1 (ru) | Лечение рака | |
| MX382904B (es) | Combinaciones de fármacos para tratar mieloma múltiple. | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| MX383748B (es) | Procesos para la preparación de un compuesto de diariltiohidantoína. | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| MX378739B (es) | Compuestos de 2-oxindol. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| CL2017000151A1 (es) | Derivados de piridona | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CO2017010143A2 (es) | Procesos para preparar fluorocetólidos | |
| MX2020012964A (es) | Metodos para el tratamiento de cancer de vejiga. | |
| MX390571B (es) | Metodos para tratamiento de cancer de ovario. | |
| UA114708U (uk) | Тяговий привід електробуса | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |